The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
| Date | Insider | Role | Action | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 11, 2026 | Wengel Kathryn E | EVP, Chief TO and Risk Officer | Option exercise(M) | 10K | $115.67 | $1.2M |
| Jun 11, 2026 | Wengel Kathryn E | EVP, Chief TO and Risk Officer | Sell(S) | 10K | $241.15 | $2.4M |
| Jun 11, 2026 | Wengel Kathryn E | EVP, Chief TO and Risk Officer | Option exercise(M) | 10K | — | $0 |
| Jun 9, 2026 | Hewson Marillyn A | Director | Grant(A) | 215 | $232.79 | $50K |
| Jun 9, 2026 | Pinto Daniel E | Director | Grant(A) | 134 | $232.79 | $31K |
| Jun 9, 2026 | Woods Eugene A. | Director | Grant(A) | 161 | $232.79 | $37K |
| May 1, 2026 | Reed John C | EVP, Innovative Medicine, R&D | Option exercise(M) | 25K | — | $0 |
| May 1, 2026 | Reed John C | EVP, Innovative Medicine, R&D | Tax withholding(F) | 11K | $229.85 | $2.5M |
| May 1, 2026 | Reed John C | EVP, Innovative Medicine, R&D | Option exercise(M) | 25K | — | $0 |
| Apr 23, 2026 | Woods Eugene A. | Director | Grant(A) | 975 | — | $0 |
| Apr 23, 2026 | West Nadja | Director | Grant(A) | 975 | — | $0 |
| Apr 23, 2026 | Weinberger Mark A | Director | Grant(A) | 975 | — | $0 |
| Apr 23, 2026 | Pinto Daniel E | Director | Grant(A) | 2K | — | $0 |
| Apr 23, 2026 | Morikis John G | Director | Grant(A) | 2K | — | $0 |
| Apr 23, 2026 | McClellan Mark B. | Director | Grant(A) | 975 | — | $0 |
| Apr 23, 2026 | Joly Hubert | Director | Grant(A) | 975 | — | $0 |
| Apr 23, 2026 | Johnson Paula A | Director | Grant(A) | 975 | — | $0 |
| Apr 23, 2026 | Hewson Marillyn A | Director | Grant(A) | 975 | — | $0 |
| Apr 23, 2026 | Doudna Jennifer A | Director | Grant(A) | 975 | — | $0 |
| Apr 23, 2026 | Beckerle Mary C | Director | Grant(A) | 975 | — | $0 |
| Mar 10, 2026 | Hewson Marillyn A | Director | Grant(A) | 206 | $242.14 | $50K |
| Mar 10, 2026 | Pinto Daniel E | Director | Grant(A) | 129 | $242.14 | $31K |
| Mar 10, 2026 | Woods Eugene A. | Director | Grant(A) | 155 | $242.14 | $37K |
| Feb 27, 2026 | Decker Robert J | VP Corporate Controller | Option exercise(M) | 4K | $115.67 | $471K |
| Feb 27, 2026 | Decker Robert J | VP Corporate Controller | Sell(S) | 4K | $247.87 | $1.0M |
| Feb 27, 2026 | Decker Robert J | VP Corporate Controller | Option exercise(M) | 4K | — | $0 |
| Feb 20, 2026 | Schmid Timothy | EVP, WW Chair, MedTech | Sell(S) | 1K | $245.66 | $325K |
| Feb 18, 2026 | Schmid Timothy | EVP, WW Chair, MedTech | Option exercise(M) | 14K | $115.67 | $1.6M |
| Feb 18, 2026 | Schmid Timothy | EVP, WW Chair, MedTech | Sell(S) | 14K | $244.20 | $3.3M |
| Feb 18, 2026 | Schmid Timothy | EVP, WW Chair, MedTech | Option exercise(M) | 9K | $129.51 | $1.2M |
| Feb 18, 2026 | Schmid Timothy | EVP, WW Chair, MedTech | Sell(S) | 9K | $244.53 | $2.2M |
| Feb 18, 2026 | Schmid Timothy | EVP, WW Chair, MedTech | Option exercise(M) | 14K | — | $0 |
| Feb 18, 2026 | Schmid Timothy | EVP, WW Chair, MedTech | Option exercise(M) | 9K | — | $0 |
| Feb 17, 2026 | Swanson James D. | EVP, CIO | Option exercise(M) | 21K | $164.62 | $3.4M |
| Feb 17, 2026 | Swanson James D. | EVP, CIO | Sell(S) | 21K | $242.70 | $5.0M |
| Feb 17, 2026 | Swanson James D. | EVP, CIO | Option exercise(M) | 21K | — | $0 |
| Feb 17, 2026 | Wolk Joseph J | Exec VP, CFO | Option exercise(M) | 19K | $115.67 | $2.2M |
| Feb 17, 2026 | Wolk Joseph J | Exec VP, CFO | Sell(S) | 19K | $242.99 | $4.7M |
| Feb 17, 2026 | Wolk Joseph J | Exec VP, CFO | Option exercise(M) | 12K | $129.51 | $1.6M |
| Feb 17, 2026 | Wolk Joseph J | Exec VP, CFO | Sell(S) | 12K | $242.87 | $2.9M |
| Feb 17, 2026 | Wolk Joseph J | Exec VP, CFO | Option exercise(M) | 33K | $131.94 | $4.4M |
| Feb 17, 2026 | Wolk Joseph J | Exec VP, CFO | Sell(S) | 33K | $242.75 | $8.1M |
| Feb 17, 2026 | Wolk Joseph J | Exec VP, CFO | Sell(S) | 25K | $242.68 | $6.1M |
| Feb 17, 2026 | Wolk Joseph J | Exec VP, CFO | Option exercise(M) | 19K | — | $0 |
| Feb 17, 2026 | Wolk Joseph J | Exec VP, CFO | Option exercise(M) | 12K | — | $0 |
| Feb 17, 2026 | Wolk Joseph J | Exec VP, CFO | Option exercise(M) | 33K | — | $0 |
| Feb 17, 2026 | Reed John C | EVP, Innovative Medicine, R&D | Option exercise(M) | 22K | $157.92 | $3.4M |
| Feb 17, 2026 | Reed John C | EVP, Innovative Medicine, R&D | Sell(S) | 22K | $243.00 | $5.3M |
| Feb 17, 2026 | Reed John C | EVP, Innovative Medicine, R&D | Option exercise(M) | 30K | $156.15 | $4.7M |
| Feb 17, 2026 | Reed John C | EVP, Innovative Medicine, R&D | Sell(S) | 30K | $243.00 | $7.3M |
| Feb 17, 2026 | Reed John C | EVP, Innovative Medicine, R&D | Sell(S) | 2K | $243.00 | $555K |
| Feb 17, 2026 | Reed John C | EVP, Innovative Medicine, R&D | Option exercise(M) | 22K | — | $0 |
| Feb 17, 2026 | Reed John C | EVP, Innovative Medicine, R&D | Option exercise(M) | 30K | — | $0 |
| Feb 17, 2026 | Broadhurst Vanessa | EVP, Global Corp Affairs | Sell(S) | 6K | $243.39 | $1.5M |
| Feb 15, 2026 | Swanson James D. | EVP, CIO | Option exercise(M) | 492 | — | $0 |
| Feb 15, 2026 | Swanson James D. | EVP, CIO | Tax withholding(F) | 214 | $243.45 | $52K |
| Feb 15, 2026 | Swanson James D. | EVP, CIO | Option exercise(M) | 709 | — | $0 |
| Feb 15, 2026 | Swanson James D. | EVP, CIO | Tax withholding(F) | 309 | $243.45 | $75K |
| Feb 15, 2026 | Swanson James D. | EVP, CIO | Option exercise(M) | 492 | — | $0 |
| Feb 15, 2026 | Swanson James D. | EVP, CIO | Option exercise(M) | 709 | — | $0 |
| Feb 15, 2026 | Swanson James D. | EVP, CIO | Grant(A) | 19K | — | $0 |
| Feb 15, 2026 | Swanson James D. | EVP, CIO | Grant(A) | 1K | — | $0 |
| Feb 15, 2026 | Wengel Kathryn E | EVP, Chief TO and Risk Officer | Option exercise(M) | 606 | — | $0 |
| Feb 15, 2026 | Wengel Kathryn E | EVP, Chief TO and Risk Officer | Tax withholding(F) | 310 | $243.45 | $75K |
| Feb 15, 2026 | Wengel Kathryn E | EVP, Chief TO and Risk Officer | Option exercise(M) | 635 | — | $0 |
| Feb 15, 2026 | Wengel Kathryn E | EVP, Chief TO and Risk Officer | Tax withholding(F) | 325 | $243.45 | $79K |
| Feb 15, 2026 | Wengel Kathryn E | EVP, Chief TO and Risk Officer | Option exercise(M) | 606 | — | $0 |
| Feb 15, 2026 | Wengel Kathryn E | EVP, Chief TO and Risk Officer | Option exercise(M) | 635 | — | $0 |
| Feb 15, 2026 | Wengel Kathryn E | EVP, Chief TO and Risk Officer | Grant(A) | 17K | — | $0 |
| Feb 15, 2026 | Wengel Kathryn E | EVP, Chief TO and Risk Officer | Grant(A) | 1K | — | $0 |
| Feb 15, 2026 | Mulholland Kristen | EVP, Chief HR Officer | Option exercise(M) | 419 | — | $0 |
| Feb 15, 2026 | Mulholland Kristen | EVP, Chief HR Officer | Tax withholding(F) | 172 | $243.45 | $42K |
| Feb 15, 2026 | Mulholland Kristen | EVP, Chief HR Officer | Option exercise(M) | 575 | — | $0 |
| Feb 15, 2026 | Mulholland Kristen | EVP, Chief HR Officer | Tax withholding(F) | 251 | $243.45 | $61K |
| Feb 15, 2026 | Mulholland Kristen | EVP, Chief HR Officer | Option exercise(M) | 419 | — | $0 |
| Feb 15, 2026 | Mulholland Kristen | EVP, Chief HR Officer | Option exercise(M) | 575 | — | $0 |
| Feb 15, 2026 | Mulholland Kristen | EVP, Chief HR Officer | Grant(A) | 20K | — | $0 |
| Feb 15, 2026 | Mulholland Kristen | EVP, Chief HR Officer | Grant(A) | 1K | — | $0 |
| Feb 15, 2026 | Wolk Joseph J | Exec VP, CFO | Option exercise(M) | 2K | — | $0 |
| Feb 15, 2026 | Wolk Joseph J | Exec VP, CFO | Tax withholding(F) | 858 | $243.45 | $209K |
| Feb 15, 2026 | Wolk Joseph J | Exec VP, CFO | Option exercise(M) | 2K | — | $0 |
| Feb 15, 2026 | Wolk Joseph J | Exec VP, CFO | Tax withholding(F) | 817 | $243.45 | $199K |
| Feb 15, 2026 | Wolk Joseph J | Exec VP, CFO | Option exercise(M) | 2K | — | $0 |
| Feb 15, 2026 | Wolk Joseph J | Exec VP, CFO | Option exercise(M) | 2K | — | $0 |
| Feb 15, 2026 | Wolk Joseph J | Exec VP, CFO | Grant(A) | 54K | — | $0 |
| Feb 15, 2026 | Wolk Joseph J | Exec VP, CFO | Grant(A) | 4K | — | $0 |
| Feb 15, 2026 | Decker Robert J | VP Corporate Controller | Option exercise(M) | 339 | — | $0 |
| Feb 15, 2026 | Decker Robert J | VP Corporate Controller | Tax withholding(F) | 94 | $243.45 | $23K |
| Feb 15, 2026 | Decker Robert J | VP Corporate Controller | Option exercise(M) | 344 | — | $0 |
| Feb 15, 2026 | Decker Robert J | VP Corporate Controller | Tax withholding(F) | 95 | $243.45 | $23K |
| Feb 15, 2026 | Decker Robert J | VP Corporate Controller | Option exercise(M) | 339 | — | $0 |
| Feb 15, 2026 | Decker Robert J | VP Corporate Controller | Option exercise(M) | 344 | — | $0 |
| Feb 15, 2026 | Decker Robert J | VP Corporate Controller | Grant(A) | 5K | — | $0 |
| Feb 15, 2026 | Decker Robert J | VP Corporate Controller | Grant(A) | 700 | — | $0 |
| Feb 15, 2026 | Reed John C | EVP, Innovative Medicine, R&D | Option exercise(M) | 1K | — | $0 |
| Feb 15, 2026 | Reed John C | EVP, Innovative Medicine, R&D | Tax withholding(F) | 385 | $243.45 | $94K |
| Feb 15, 2026 | Reed John C | EVP, Innovative Medicine, R&D | Option exercise(M) | 2K | — | $0 |
| Feb 15, 2026 | Reed John C | EVP, Innovative Medicine, R&D | Tax withholding(F) | 528 | $243.45 | $129K |
| Feb 15, 2026 | Reed John C | EVP, Innovative Medicine, R&D | Option exercise(M) | 1K | — | $0 |
| Feb 15, 2026 | Reed John C | EVP, Innovative Medicine, R&D | Option exercise(M) | 2K | — | $0 |
Insider transactions sourced from SEC EDGAR Form 4 filings, normalized within minutes of acceptance. "Buy"/"Sell" mark open-market transactions (codes P/S), the tradeable signal. Awards, option exercises and tax-withholding are shown with their raw code. All data is public domain.
Coverage: Form 4 filings indexed 2021-01-04 → 2026-07-18. Earlier history is backfilling; this window widens as it deepens.
Programmatic access via the Arkolith API & MCP server (insider.transactions, insider.company).